الوصف
Glycemic control parameters including HbA1c and fasting glucose in diabetic patients supplemented with EPA versus DHA are compared across clinical trials.
Figure 31
Source Paper
Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?Cite This Figure
![Figure 31: Glycemic control parameters including HbA1c and fasting glucose in diabetic patients supplemented with EPA versus DHA are compared across clinical trials.]() > Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." *Nutrients*, 2020. PMID: [33276463](https://pubmed.ncbi.nlm.nih.gov/33276463/)
<figure> <img src="" alt="Glycemic control parameters including HbA1c and fasting glucose in diabetic patients supplemented with EPA versus DHA are compared across clinical trials." /> <figcaption>Figure 31. Glycemic control parameters including HbA1c and fasting glucose in diabetic patients supplemented with EPA versus DHA are compared across clinical trials.<br> Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33276463/">33276463</a></figcaption> </figure>